PDF herunterladen
Neuropediatrics 2023; 54(01): 014-019
DOI: 10.1055/s-0042-1757706
Original Article

Autoimmune Encephalitis with Autoantibodies to NMDAR1 following Herpes Encephalitis in Children and Adolescents

Annegret Quade 
1   Department of Pediatrics, Division of Neuropediatrics and Social Pediatrics, Medical Faculty, RWTH Aachen University, Aachen, Germany
,
Kevin Rostasy
2   Department of Paediatric Neurology, Children's Hospital Datteln, Witten/Herdecke University, Witten, Germany
,
Ronny Wickström
3   Department of Women's and Children's Health, Division of Neuropediatrics, Karolinska Institute, Solna, Sweden
,
Ömer Faruk Aydin
4   Department of Pediatric Neurology, Medical Faculty, Ondokuz Mayis University, Turkey
,
Stefano Sartori
5   Department of Women's and Children's Health, Paediatric Neurology and Neurophysiology Unit, University Hospital of Padua, Padua, Italy and Neuroimmunology Group, Paediatric Research Institute “Città della Speranza,” Padova, Italy
,
Margherita Nosadini
5   Department of Women's and Children's Health, Paediatric Neurology and Neurophysiology Unit, University Hospital of Padua, Padua, Italy and Neuroimmunology Group, Paediatric Research Institute “Città della Speranza,” Padova, Italy
,
Ellen Knierim
6   Department of Neuropediatrics, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany
,
Gerhard Kluger
7   Clinic for Neuropediatrics and Neurorehabilitation, Epilepsy Center for Children and Adolescents, Schön Klinik, Vogtareuth, Germany
8   Research Institute “Rehabilitation-Transition-Palliation,” PMU Salzburg, Austria
,
Rudolf Korinthenberg 
9   Department of Neuropediatrics and Muscular Disorders, Medical Faculty, University of Freiburg, Freiburg, Germany
,
Burkhard Stüve
10   Department of Neuropediatrics, Children's Hospital Siegen, Germany
,
Stephan Waltz
11   Neuropediatric Department, Children's Hospital Cologne, Germany
,
Steffen Leiz
12   Department of Pediatrics, Neuropediatrics, Klinikum Dritter Orden München – Nymphenburg, Germany
,
Martin Häusler 
1   Department of Pediatrics, Division of Neuropediatrics and Social Pediatrics, Medical Faculty, RWTH Aachen University, Aachen, Germany
› Institutsangaben
› Weitere Informationen
   Artikel einzeln kaufen Lizenzen und Reprints

Abstract

Herpes simplex virus (HSV) type 1 is a frequent pathogen causing infectious encephalitis (HSVE). Early treatment with intravenous acyclovir has led to a significant decrease in mortality. However, especially in children, deterioration during or after HSVE may occur without any evidence of HSV reactivation or improvement following repeated antiviral therapy. Here, we report 15 patients (age range 3 months to 15 years) who suffered from autoimmune encephalitis with autoantibodies to NMDAR1 following Herpes encephalitis, presenting with movement abnormalities (young children) or neuropsychiatric symptoms (older children) as major complaints, respectively. The diagnosis was based on positive cerebrospinal fluid (CSF) and/or serum anti-NMDAR-antibodies with two children showing only positive CSF antibody findings. The time lag between first symptoms and diagnosis of autoimmune encephalitis was significantly longer than between first symptoms and diagnosis of HSVE (p <0.01). All patients improved during immunosuppressive treatment, during which plasmapheresis or rituximab treatments were applied in 11 patients, irrespective of their age. Despite immunotherapy, no patients relapsed with HSVE. Early diagnosis and treatment of autoimmune encephalitis after HSVE may be associated with a better outcome so that high clinical awareness and routine testing for anti-NMDAR-antibodies after HSVE seems advisable. If autoimmune encephalitis is suspected, antibody testing should also be performed on CSF if negative in serum.

Keywords

Herpes simplex encephalitis - autoimmune encephalitis - anti- NMDAR antibodies

Supplementary Material



Publikationsverlauf

Eingereicht: 11. November 2021

Angenommen: 12. August 2022

Artikel online veröffentlicht:
21. Dezember 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Granerod J, Ambrose HE, Davies NW. et al; UK Health Protection Agency (HPA) Aetiology of Encephalitis Study Group. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis 2010; 10 (12) 835-844
    CrossrefPubMedGoogle Scholar
  • 2 Boston Interhospital Virus Study Group; NIAID-Sponsored Cooperative Antiviral Clinical Study. Failure of high dose 5-iodo-2′-deoxyuridine in the therapy of herpes simplex virus encephalitis. Evidence of unacceptable toxicity. N Engl J Med 1975; 292 (12) 599-603
    CrossrefPubMedGoogle Scholar
  • 3 Sköldenberg B, Forsgren M, Alestig K. et al. Acyclovir versus vidarabine in herpes simplex encephalitis. Randomised multicentre study in consecutive Swedish patients. Lancet 1984; 2 (8405): 707-711
    CrossrefPubMedGoogle Scholar
  • 4 De Tiège X, Rozenberg F, Des Portes V. et al. Herpes simplex encephalitis relapses in children: differentiation of two neurologic entities. Neurology 2003; 61 (02) 241-243
    CrossrefPubMedGoogle Scholar
  • 5 Gutman LT, Wilfert CM, Eppes S. Herpes simplex virus encephalitis in children: analysis of cerebrospinal fluid and progressive neurodevelopmental deterioration. J Infect Dis 1986; 154 (03) 415-421
    CrossrefPubMedGoogle Scholar
  • 6 Ito Y, Kimura H, Yabuta Y. et al. Exacerbation of herpes simplex encephalitis after successful treatment with acyclovir. Clin Infect Dis 2000; 30 (01) 185-187
    CrossrefPubMedGoogle Scholar
  • 7 Schleede L, Bueter W, Baumgartner-Sigl S. et al. Pediatric herpes simplex virus encephalitis: a retrospective multicenter experience. J Child Neurol 2013; 28 (03) 321-331
    CrossrefPubMedGoogle Scholar
  • 8 Sköldenberg B, Aurelius E, Hjalmarsson A. et al. Incidence and pathogenesis of clinical relapse after herpes simplex encephalitis in adults. J Neurol 2006; 253 (02) 163-170
    CrossrefPubMedGoogle Scholar
  • 9 Lafaille FG, Pessach IM, Zhang SY. et al. Impaired intrinsic immunity to HSV-1 in human iPSC-derived TLR3-deficient CNS cells. Nature 2012; 491 (7426): 769-773
    CrossrefPubMedGoogle Scholar
  • 10 Armangue T, Spatola M, Vlagea A. et al; Spanish Herpes Simplex Encephalitis Study Group. Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. Lancet Neurol 2018; 17 (09) 760-772
    CrossrefPubMedGoogle Scholar
  • 11 Nosadini M, Mohammad SS, Corazza F. et al. Herpes simplex virus-induced anti-N-methyl-d-aspartate receptor encephalitis: a systematic literature review with analysis of 43 cases. Dev Med Child Neurol 2017; 59 (08) 796-805
    CrossrefPubMedGoogle Scholar
  • 12 Marcus L, Ness JM. Pediatric N-Methyl-d-Aspartate (NMDA) receptor encephalitis, with and without herpes encephalitis. J Child Neurol 2021; 36 (09) 743-751
    CrossrefPubMedGoogle Scholar
  • 13 Dalmau J, Tüzün E, Wu HY. et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007; 61 (01) 25-36
    CrossrefPubMedGoogle Scholar
  • 14 Dalmau J, Gleichman AJ, Hughes EG. et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008; 7 (12) 1091-1098
    CrossrefPubMedGoogle Scholar
  • 15 Favier M, Joubert B, Picard G. et al. Initial clinical presentation of young children with N-methyl-d-aspartate receptor encephalitis. Eur J Paediatr Neurol 2018; 22 (03) 404-411
    CrossrefPubMedGoogle Scholar
  • 16 Florance NR, Davis RL, Lam C. et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol 2009; 66 (01) 11-18
    CrossrefPubMedGoogle Scholar
  • 17 Goenka A, Jain V, Nariai H, Spiro A, Steinschneider M. Extended clinical spectrum of anti-N-methyl-d-aspartate receptor encephalitis in children: a case series. Pediatr Neurol 2017; 72: 51-55
    CrossrefPubMedGoogle Scholar
  • 18 Hara M, Martinez-Hernandez E, Ariño H. et al. Clinical and pathogenic significance of IgG, IgA, and IgM antibodies against the NMDA receptor. Neurology 2018; 90 (16) e1386-e1394
    CrossrefPubMedGoogle Scholar
  • 19 Prüss H, Finke C, Höltje M. et al. N-methyl-D-aspartate receptor antibodies in herpes simplex encephalitis. Ann Neurol 2012; 72 (06) 902-911
    CrossrefPubMedGoogle Scholar
  • 20 Titulaer MJ, McCracken L, Gabilondo I. et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013; 12 (02) 157-165
    CrossrefPubMedGoogle Scholar
  • 21 Martinez-Hernandez E, Horvath J, Shiloh-Malawsky Y, Sangha N, Martinez-Lage M, Dalmau J. Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis. Neurology 2011; 77 (06) 589-593
    CrossrefPubMedGoogle Scholar
  • 22 Al-Obaidi MMJ, Bahadoran A, Wang SM, Manikam R, Raju CS, Sekaran SD. Disruption of the blood brain barrier is vital property of neurotropic viral infection of the central nervous system. Acta Virol 2018; 62 (01) 16-27
    CrossrefPubMedGoogle Scholar
  • 23 Bartels F, Krohn S, Nikolaus M. et al. Clinical and magnetic resonance imaging outcome predictors in pediatric anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol 2020; 88 (01) 148-159
    CrossrefPubMedGoogle Scholar